Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm

Curr Opin Neurol. 2018 Jun;31(3):233-243. doi: 10.1097/WCO.0000000000000561.

Abstract

Purpose of review: The treatment of multiple sclerosis is evolving rapidly with 11 classes of disease-modifying therapies (DMTs). This article provides an overview of a new classification system for DMTs and treatment paradigm for using these DMTs effectively and safely.

Recent findings: A summary of research into the use of more active approaches to early and effective treatment of multiple sclerosis with defined treatment targets of no evident disease activity (NEDA). New insights are discussed that is allowing the field to begin to tackle more advanced multiple sclerosis, including people with multiple sclerosis using wheelchairs. However, the need to modify expectations of what can be achieved in more advanced multiple sclerosis are discussed; in particular, the focus on neuronal systems with reserve capacity, for example, upper limb, bulbar and visual function.

Summary: The review describes a new more active way of managing multiple sclerosis and concludes with a call to action in solving the problem of slow adoption of innovations and the global problem of untreated, or undertreated, multiple sclerosis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Humans
  • Immunologic Factors / therapeutic use*
  • Multiple Sclerosis / drug therapy*
  • Treatment Outcome

Substances

  • Immunologic Factors